Skip to main content
. 2021 Aug 19;11:711043. doi: 10.3389/fonc.2021.711043

Figure 1.

Figure 1

GZ17-6.02 interacts with ERBB1 inhibitors to kill NSCLC cells expressing mutant active forms of ERBB1. (A, B) H1650, wild-type sensitive, and afatinib-resistant (AR) H1975 and erlotinib-resistant (ER) HCC827 cells were treated with vehicle, erlotinib (500 nM), afatinib (500 nM), GZ17-6.02 (2 μM curcumin final), or the drugs in combination for 24 h. Cell viability was determined by trypan blue exclusion (n = 3 ± SD). # p < 0.05 greater than GZ17-6.02 alone; p < 0.05 less than the corresponding values in drug-sensitive cells. (C) H1650, wild-type sensitive, and afatinib-resistant (AR) H1975 and erlotinib-resistant (ER) HCC827 cells were treated with vehicle, osimertinib (100 nM), GZ17-6.02 (2 μM curcumin final), or the drugs in combination for 24 h. Cell viability was determined by trypan blue exclusion (n = 3 ± SD). # p < 0.05 greater than GZ17-6.02 alone; p < 0.05 less than the corresponding values in drug-sensitive cells.